An interventional study of Cardiac CT in Coronary Artery Diease, sponsored by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio. Recruiting at 1 site in Italy. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Atherosclerosis with a site in Italy — 12 open to participants now, 22 under way, 10 of them phase 3. Atherosclerosis · Italy.
Among the 81 studies in Atherosclerosis with a site in Italy, this one is the 31st largest by planned enrollment of the 51 interventional ones that give a count, is one of 6 that started in 2025, is one of 20 with no phase, reaches primary completion later than 7 of the 21 other live ones, and was the 78th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →12 of the 81 studies in Atherosclerosis with a site in Italy are open now. Recruiting first, the newest first:
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Sites in Italy, France, Netherlands and 1 more country
Ages 12+
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
Eli Lilly and Company · Sites in Italy, United States, Argentina and 25 more countries
Ages 18+
AstraZeneca · Sites in Italy, United States, Argentina and 33 more countries
Ages 18+
CSL Behring · Sites in Italy, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 20 · Phase 4 6
First in 1996; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 423 across the 51 interventional studies, 312 across the 29 observational. Of the 43 that completed or were terminated, 15 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 81 have an industry lead sponsor. The 10 most frequent:
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio is the lead sponsor of 161 studies on the registry; 59 are open to participants now.
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Atherosclerosis with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06230406IRCCS Policlinico S. DonatoT-Mem GEne in Atherosclerosis | 2026-12 |
| NCT07352111I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioHigh-risk Coronary Atherosclerosis in Subjects With Family History of Myocardial Infarction | 2026-12-31 |
| NCT07447648Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 81 studies in Atherosclerosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The evidence of high-risk atherosclerosis at cardiac CT (CCT) may support aggressive primary prevention treatment, reducing the risk of future cardiovascular events. Family history of coronary artery disease (CAD) is a risk factor for cardiovascular events but limited data described the prevalence of coronary atherosclerosis in these patients.
Aims of the FAMILY project are to explore the prevalence of high-risk coronary atherosclerosis among patients with family history of CAD, to explore whether CCT in this setting may to reclassify patients' vs standard of care and to explore correlations between genetic background and high risk and potentially unstable coronary atherosclerosis.
A consecutive cohort of asymptomatic of patients with family history of CAD will be prospectively enrolled. A per-protocol CCT with advanced atherosclerosis analysis will be performed. At the time of CCT a blood sample will be collected for bio-humoral and genetic investigation. The prevalence of high risk atherosclerosis will be quantified, the reclassification rate of CCT vs clinical evaluation evaluated and the potential in vivo association between genetic profile and high risk atherosclerosis explored.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients asymptomatic but with family history of CAD will undergo cardiac CT with advance plaque evaluation
Diagnostic Test: Cardiac CT
Cardiac CT with advance plaque evaluation will be performed
Risk reclassification
Risk reclassification rate will be evaluated
Time frame: 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 12 months is below that.
Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio →